Top news of the week: 08.11.2022.
Here’s why we’re not prepared for the next wave of biotech innovation
This is "biology's century," @matthewherper writes. But we’re approaching a moment when changes in what we understand are every bit as terrifying as exhilarating.
Duke, MIT, and Stanford scientists create RNA technology that could improve genetic therapies
The researchers are already envisioning a bevy of applications in basic research, diagnostics, and therapeutics.
Building a biotech in a downturn: 3 lessons from VCs and startup CEOs
In a panel discussion hosted by BioPharma Dive, venture capitalists and CEOs discussed how startups can navigate a challenging market as well as possible ripple effects from the new U.S. ...
California Congressman Josh Harder’s FARM Bill Could Revolutionize The Central Valley’s Biotech Ecosystem And Turn Almond Husks Into Yoga Pants
California’s leadership is rising to the challenge: last year, state Representative Josh Harder reintroduced his Future of Agricultural Resiliency and Modernization (FARM) Act aimed to help ...
Artiva cancels IPO plans and cuts a deal with Affimed
With public offerings difficult to pull off, Artiva is focusing its energy on a cancer drug deal with the German biotech.
Hate needles? Flu vaccines of the future could be skin patches delivered to your door.
Vaxess, a Cambridge startup with ties to Harvard, MIT, and Tufts, raised $27 million to test its technology in clinical trials after developing the idea for more than a decade.
RA Capital backs another startup hunting for a better antidepressant
Lusaris Therapeutics is launching with $60 million to develop an under-the-tongue form of 5-MeO-DMT, a psychoactive compound found in the glands of the Sonoran Desert toad.
Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022
/PRNewswire/ -- At its annual R&D investor briefing today, global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) demonstrated how its growing, innovative...